益心舒胶囊联合替格瑞洛片对不稳定型心绞痛患者心功能、血脂和血液流变学的影响

摘要 目的：探讨益心舒胶囊联合替格瑞洛片对不稳定型心绞痛（UAP）患者心功能、血脂和血液流变学的影响。方法：选择2021年4月~2022年5月期间来我院接受治疗的UAP患者108例。根据随机数字表法分为对照组（n=54）和研究组（n=54），在常规治疗的基础上，对照组患者接受替格瑞洛片治疗，研究组患者接受益心舒胶囊联合替格瑞洛片治疗。对比两组疗效、血脂指标、心功能指标、血液流变学指标、临床指标和不良反应。结果：研究组的临床总有效率高于对照组（P<0.05）。治疗后，研究组的左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）小于对照组，左心室射血分数（LVEF）高于对照组（P<0.05）。治疗后，研究组三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）低于对照组，高密度脂蛋白胆固醇（HDL-C）高于对照组（P<0.05）。治疗后，研究组的血浆黏度、全血高切黏度、全血低切黏度、纤维蛋白原低于对照组（P<0.05）。治疗后，研究组的心绞痛发作频率、硝酸甘油日消耗量少于对照组，发作持续时间短于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：UAP患者采用益心舒胶囊联合替格瑞洛片治疗，临床症状明显改善，同时还可改善心功能、血脂和血液流变学。

Effects of Yixinshu Capsule Combined with Ticagrelor Tablets on Cardiac Function, Blood Lipid and Hemorheology in Patients with Unstable Angina Pectoris

ABSTRACT Objective: To investigate the effects of Yixinshu capsule combined with ticagrelor tablets on cardiac function, blood lipid and hemorheology in patients with unstable angina pectoris (UAP). Methods: 108 patients with UAP who came to our hospital for treatment from April 2021 to May 2022 were selected. According to the method of random number table, they were divided into the control group (n=54) and the study group (n=54). On the basis of conventional treatment, patients of the control group were treated with ticagrelor tablets, and patients of the study group were treated with Yixinshu capsule combined with ticagrelor tablets. The curative effect, blood lipid index, cardiac function index, hemorheology index, clinical index and adverse reaction of the two groups were compared. Results: The total clinical effective rate of the study group was higher than that of the control group (P<0.05). After treatment, the left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD) of the study group were smaller than those of the control group, and the left ventricular ejection fraction (LVEF) was higher than that of the control group(P<0.05). After treatment, triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) of the study group were lower than those of the control group, while high-density lipoprotein cholesterol (HDL-C) was higher than that of the control group (P<0.05). After treatment, the plasma viscosity, whole blood high shear viscosity, whole blood low shear viscosity and fibrinogen of the study group were lower than those of the control group(P<0.05). After treatment, the frequency of angina pectoris attack, the daily consumption of nitroglycerin of the study group were less than those of the control group, and the duration of the attack was shorter than that of the control group (P<0.05). There was no difference in the incidence of adverse reactions of the two groups (P>0.05). Conclusion: The patients with UAP are treated with Yixinshu capsule combined with ticagrelor tablets, and the clinical symptoms are improved significantly. At the same time, the cardiac function, blood lipid and hemorheology are improved.